Posters

Fluorescein angiographic findings of type 1 and type 2 retinopathy of prematurity with and without intravitreal bevacizumab monotherapy

Poster Details

First Author: I.Perente TURKEY

Co Author(s):    A. Vural   D. Ekinci   U. Onur   Z. Seymen                    

Abstract Details



Purpose:

To investigate the extent of vascularization of the peripheral retina and vascular development patterns in patients with type 1 Retinopathy of Prematurity (ROP) in zone I and posterior zone II who were treated with a single intravitreal injection of bevacizumab 0.025 ml (0.625mg), and in patients with type 2 ROP who were followed without treatment. The progress of ROP was evaluated with fluorescein angiographic findings in patients with type 1 and type 2 ROP.

Setting:

this is a retrospective descriptive study

Methods:

Medical records of the patients who undergone single dose of intravitreal bevacizumab injection treatment for zone I and posterior zone II type 1 ROP and type 2 ROP without any treatment were studied. All of the patients were examined with RetCam III (Clarity Medical Systems, Pleasanton, CA) under general anaesthesia and using a contact gel. Wide-angle coloured fundus images of the retina and corresponding FAs were captured bilaterally for all babies.

Results:

74 eyes of 37 premature infants were included in the study; 48 eyes of 24 patients were treated for type 1 ROP and 26 eyes of 13 patients were diagnosed as type 2 ROP. On the FA examination vascular terminal was found to be in zone 2 in 10 eyes of 5 patients (20.8%), in zone 3 with more then 2 disc diameters (DD) from temporal ora serrata in 16 eyes of 8 patients (33.3%), in zone 3 with less then 2 DD from temporal ora serrata in 22 eyes of 11 patients (45.8%) in type 1 ROP group. In all eyes of type 2 ROP group (100%), vascular terminal was in zone 3 with less then 2 DD from temporal ora serrata. We noted circumferential vessels in 19 eyes of 10 patients In type 1 group and 4 eyes of 2 patients in type 2 group; closely packed multiple bridging arteriovenous shunts in 6 eyes of 3 patient In type 1 group and in 3 eyes of 3 patients In type 2 group; irregular arteriolar branching in 3 eyes of 2 patient In type 1 group and in 13 eyes of 7 patients In type 2 group.

Conclusions:

Peripheral vascular abnormalities can be detected both in type 1 and type 2 ROP patients. Anti-VEGF drugs slow down vascularization as they reduced VEGF level but if enough time passes vascularization can reach the farthermost limits at the end.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy